• Je něco špatně v tomto záznamu ?

A validation study of potential prognostic DNA methylation biomarkers in patients with acute myeloid leukemia using a custom DNA methylation sequencing panel

Š. Šestáková, E. Cerovská, C. Šálek, D. Kundrát, I. Ježíšková, A. Folta, J. Mayer, Z. Ráčil, P. Cetkovský, H. Remešová

. 2022 ; 14 (1) : 22. [pub] 20220211

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22011025

Grantová podpora
00023736 Ministerstvo Zdravotnictví Ceské Republiky
IHBT Ministerstvo Zdravotnictví Ceské Republiky

BACKGROUND: Multiple studies have reported the prognostic impact of DNA methylation changes in acute myeloid leukemia (AML). However, these epigenetic markers have not been thoroughly validated and therefore are still not considered in clinical practice. Hence, we aimed to independently verify results of selected studies describing the relationship between DNA methylation of specific genes and their prognostic potential in predicting overall survival (OS) and event-free survival (EFS). RESULTS: Fourteen studies (published 2011-2019) comprising of 27 genes were subjected to validation by a custom NGS-based sequencing panel in 178 newly diagnosed non-M3 AML patients treated by 3 + 7 induction regimen. The results were considered as successfully validated, if both the log-rank test and multivariate Cox regression analysis had a p-value ≤ 0.05. The predictive role of DNA methylation was confirmed for three studies comprising of four genes: CEBPA (OS: p = 0.02; EFS: p = 0.03), PBX3 (EFS: p = 0.01), LZTS2 (OS: p = 0.05; EFS: p = 0.0003), and NR6A1 (OS: p = 0.004; EFS: p = 0.0003). For all of these genes, higher methylation was an indicator of longer survival. Concurrent higher methylation of both LZTS2 and NR6A1 was highly significant for survival in cytogenetically normal (CN) AML group (OS: p < 0.0001; EFS: p < 0.0001) as well as for the whole AML cohort (OS: p = 0.01; EFS < 0.0001). In contrast, for two studies reporting the poor prognostic effect of higher GPX3 and DLX4 methylation, we found the exact opposite, again linking higher GPX3 (OS: p = 0.006; EFS: p < 0.0001) and DLX4 (OS: p = 0.03; EFS = 0.03) methylation to a favorable treatment outcome. Individual gene significance levels refer to the outcomes of multivariate Cox regression analysis. CONCLUSIONS: Out of twenty-seven genes subjected to DNA methylation validation, a prognostic role was observed for six genes. Therefore, independent validation studies are necessary to reveal truly prognostic DNA methylation changes and to enable the introduction of these promising epigenetic markers into clinical practice.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22011025
003      
CZ-PrNML
005      
20220506131252.0
007      
ta
008      
220425s2022 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s13148-022-01242-6 $2 doi
035    __
$a (PubMed)35148810
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Šestáková, Šárka $u Department of Genomics, Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20, Prague 2, Czech Republic $u Institute of Clinical and Experimental Hematology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
245    12
$a A validation study of potential prognostic DNA methylation biomarkers in patients with acute myeloid leukemia using a custom DNA methylation sequencing panel / $c Š. Šestáková, E. Cerovská, C. Šálek, D. Kundrát, I. Ježíšková, A. Folta, J. Mayer, Z. Ráčil, P. Cetkovský, H. Remešová
520    9_
$a BACKGROUND: Multiple studies have reported the prognostic impact of DNA methylation changes in acute myeloid leukemia (AML). However, these epigenetic markers have not been thoroughly validated and therefore are still not considered in clinical practice. Hence, we aimed to independently verify results of selected studies describing the relationship between DNA methylation of specific gen $a BACKGROUND Multiple studies have reported the prognostic impact of DNA methylation changes in acute myeloid leukemia AML However these epigenetic markers have not been thoroughly validated and therefore are still not considered in clinical practice Hence we aimed to independently verify results of selected studies describing the relationship between DNA methylation of specific genes and $a BACKGROUND: Multiple studies have reported the prognostic impact of DNA methylation changes in acute myeloid leukemia (AML). However, these epigenetic markers have not been thoroughly validated and therefore are still not considered in clinical practice. Hence, we aimed to independently verify results of selected studies describing the relationship between DNA methylation of specific genes and their prognostic potential in predicting overall survival (OS) and event-free survival (EFS). RESULTS: Fourteen studies (published 2011-2019) comprising of 27 genes were subjected to validation by a custom NGS-based sequencing panel in 178 newly diagnosed non-M3 AML patients treated by 3 + 7 induction regimen. The results were considered as successfully validated, if both the log-rank test and multivariate Cox regression analysis had a p-value ≤ 0.05. The predictive role of DNA methylation was confirmed for three studies comprising of four genes: CEBPA (OS: p = 0.02; EFS: p = 0.03), PBX3 (EFS: p = 0.01), LZTS2 (OS: p = 0.05; EFS: p = 0.0003), and NR6A1 (OS: p = 0.004; EFS: p = 0.0003). For all of these genes, higher methylation was an indicator of longer survival. Concurrent higher methylation of both LZTS2 and NR6A1 was highly significant for survival in cytogenetically normal (CN) AML group (OS: p < 0.0001; EFS: p < 0.0001) as well as for the whole AML cohort (OS: p = 0.01; EFS < 0.0001). In contrast, for two studies reporting the poor prognostic effect of higher GPX3 and DLX4 methylation, we found the exact opposite, again linking higher GPX3 (OS: p = 0.006; EFS: p < 0.0001) and DLX4 (OS: p = 0.03; EFS = 0.03) methylation to a favorable treatment outcome. Individual gene significance levels refer to the outcomes of multivariate Cox regression analysis. CONCLUSIONS: Out of twenty-seven genes subjected to DNA methylation validation, a prognostic role was observed for six genes. Therefore, independent validation studies are necessary to reveal truly prognostic DNA methylation changes and to enable the introduction of these promising epigenetic markers into clinical practice.
650    _2
$a dospělí $7 D000328
650    _2
$a nádorové biomarkery $x analýza $x genetika $7 D014408
650    _2
$a metylace DNA $x genetika $x fyziologie $7 D019175
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a imunochemie $x metody $x statistika a číselné údaje $7 D007120
650    _2
$a akutní myeloidní leukemie $x diagnóza $x genetika $7 D015470
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prognóza $7 D011379
650    _2
$a sekvenční analýza DNA $x metody $x statistika a číselné údaje $7 D017422
650    _2
$a transkripční faktory $x genetika $7 D014157
650    _2
$a výsledek terapie $7 D016896
650    _2
$a validační studie jako téma $7 D054928
655    _2
$a časopisecké články $7 D016428
700    1_
$a Cerovská, Ela $u Department of Genomics, Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20, Prague 2, Czech Republic $u Faculty of Science, Charles University, Prague, Czech Republic
700    1_
$a Šálek, Cyril $u Department of Genomics, Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20, Prague 2, Czech Republic $u Institute of Clinical and Experimental Hematology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Kundrát, Dávid $u Department of Genomics, Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20, Prague 2, Czech Republic
700    1_
$a Ježíšková, Ivana $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Folta, Adam $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Mayer, Jiří $u Department of Internal Medicine-Hematology and Oncology, University Hospital Brno, Brno, Czech Republic
700    1_
$a Ráčil, Zdeněk $u Department of Genomics, Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20, Prague 2, Czech Republic
700    1_
$a Cetkovský, Petr $u Department of Genomics, Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20, Prague 2, Czech Republic $u Institute of Clinical and Experimental Hematology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Remešová, Hana $u Department of Genomics, Institute of Hematology and Blood Transfusion, U Nemocnice 1, 128 20, Prague 2, Czech Republic. hana.remesova@uhkt.cz $1 https://orcid.org/0000000229678355 $7 xx0121176
773    0_
$w MED00186202 $t Clinical epigenetics $x 1868-7083 $g Roč. 14, č. 1 (2022), s. 22
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35148810 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506131244 $b ABA008
999    __
$a ok $b bmc $g 1788895 $s 1162223
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 14 $c 1 $d 22 $e 20220211 $i 1868-7083 $m Clinical epigenetics $n Clin Epigenetics $x MED00186202
GRA    __
$a 00023736 $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a IHBT $p Ministerstvo Zdravotnictví Ceské Republiky
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Možnosti archivace